Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Vitamin C, ROS/NF-κB, and Cochlear Senescence
2026-08-17
A 2024 Molecular Biology Reports study shows that ascorbic acid reduces D-galactose-induced senescence in HEI-OC1 cochlear hair cells. The findings connect improved cell viability and lower inflammatory stress with suppression of the ROS/NF-κB pathway, while also defining important limits for translation to age-related hearing loss.
-
PBA-Targeted PAD4 Inhibitors Block NET-Driven Tumors
2026-08-17
The reference study develops phenylboronic acid-modified PAD4 inhibitors to improve tumor targeting and suppress the PAD4–H3cit–NET pathway in neutrophils. Its lead compound, 5i, reduced tumor growth and lung metastasis in mouse models while showing limited direct tumor-cell killing, highlighting a microenvironment-focused strategy for PAD4-directed therapy.
-
Doxycycline hyclate for MMP-Driven BBB Research
2026-08-16
Doxycycline hyclate is a practical matrix metalloproteinases inhibitor for connecting MMP activity with blood-brain barrier failure, neuronal apoptosis, and behavioral outcomes. This workflow-focused guide shows how to reproduce the arsenic neurotoxicity model, control solubility and vehicle effects, and extend the reagent cautiously into neurovascular, antiviral, and antimalarial assays.
-
LEE011 Succinate: CDK Inhibitor Workflow Guide
2026-08-15
Build reproducible CDK4/6 experiments with LEE011 succinate by aligning formulation, dosing, cell-cycle readouts, and longitudinal sampling. The workflow distinguishes cytostatic activity from nonspecific toxicity and adapts a clinically informed biomarker-design principle without overstating cross-domain evidence.
-
KPT330 and Cas9 mRNA Nuclear Export
2026-08-14
The reference study identified selective inhibitors of nuclear export, including KPT330, as indirect small-molecule modulators that improve the precision of Cas9 genome and base editing in human cells. Its central contribution is to show that regulating Cas9 mRNA export can control editing activity upstream of Cas9 protein function, creating a new temporal strategy for limiting off-target events.
-
Cy5-UTP: A Readout Strategy for mRNA Delivery
2026-08-14
Cy5-UTP enables direct fluorescent RNA labeling while offering a practical way to interrogate mRNA synthesis, integrity, and nanoparticle delivery workflows. This article connects RNA probe design with the lung-targeted LNP strategy reported in ACS Applied Materials & Interfaces, emphasizing assay decisions, controls, and limitations.
-
Ibotenic Acid for Neural Circuit Research
2026-08-13
Ibotenic acid is a research-grade NMDA receptor agonist for controlled glutamatergic perturbation, focal neuronal lesion studies, and animal models of neurodegenerative disorders. This guide connects formulation and quality-control decisions with circuit-level pain assays, highlighting where excitotoxic lesioning complements—and where it cannot replace—genetic or pharmacological manipulation.
-
Exosomal SNORD52 Activates JAK2/STAT6 in HCC
2026-08-13
The reference study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular regulator of M2 macrophage polarization in hepatocellular carcinoma. By combining exosome analysis, THP-1 macrophage assays, qRT-PCR, western blotting, and flow cytometry, the authors connect transferred SNORD52 with activation of the JAK2/STAT6 pathway and provide a framework for studying tumor–immune communication.
-
JNJ-26854165 (Serdemetan) Assay Workflow
2026-08-12
Build more informative p53-pathway experiments with JNJ-26854165 (Serdemetan), from solvent handling and dose-response design to separate measurements of growth inhibition and cell death. This workflow also shows how to evaluate apoptosis and radiation enhancement without confusing reduced viability with confirmed cytotoxicity.
-
Sodium Picosulfate in Gut–Brain Research
2026-08-12
Sodium Picosulfate offers a controllable way to study intestinal water handling, stool output, and transit-related confounding in constipation and gut–liver–brain models. This research-focused guide connects its formulation advantages with [18F]PBR146 micro-PET/CT workflows while clearly separating established evidence from exploratory applications.
-
Bovine Insulin in ER-Stress Cell Assays
2026-08-11
Bovine insulin can be more than a routine culture supplement: it is a controllable metabolic variable in hepatocyte and ER-stress experiments. This guide connects insulin signaling pathway design with the QRICH1–HMGB1 findings reported in HBV-associated liver injury while defining practical limits for interpretation.
-
CX-4945: Practical CK2 Inhibition Workflows
2026-08-11
CX-4945 (Silmitasertib) enables mechanistic CK2 studies that connect phosphorylation control with apoptosis, cell-cycle behavior, stemness, and drug resistance. This guide translates lung cancer findings into practical dosing, assay-design, and troubleshooting strategies for reproducible cancer biology workflows.
-
THZ1 and Nuclear-Pore Assay Logic in T-Cell Research
2026-08-10
THZ1 is a covalent CDK7 inhibitor with a distinctive mechanism for probing transcription-dependent cancer phenotypes. This article connects THZ1 assay design with new evidence that signaling, nuclear transport, and cellular state can create hidden experimental bottlenecks.
-
2′-O-Galloylhyperin as a TSHR Antagonist in TED
2026-08-09
A 2025 Journal of Clinical Endocrinology & Metabolism study used structure-based virtual screening and patient-derived orbital fibroblast models to identify 2′-O-galloylhyperin as a candidate inhibitor of thyrotropin receptor signaling. The compound reduced cAMP-CREB activity, adipogenesis, hyaluronan deposition, fibrosis-associated behavior, and cell proliferation in vitro, supporting further investigation while leaving questions about direct binding, pharmacological exposure, and clinical efficacy unresolved.
-
NHS-Biotin: Amine-Reactive Labeling Guide
2026-08-08
NHS-Biotin, also called N-hydroxysuccinimido biotin, labels accessible primary amines through stable amide-bond formation. Its short 13.5 Å spacer arm, organic-solvent formulation, and membrane permeability support protein detection, purification, and intracellular labeling workflows.